8-K filing — TELA Bio, Inc. (TELA)
Filed: 2026-10-06 AccNo: 0001104659-26-114042 Size: 186 KB Item 8.01: Other Events
Stocks · News reference
TELA Bio Q2 EPS $(0.20) Misses $(0.18) Estimate, Sales $19.291M Miss $20.008M Estimate
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 9.09 percent increase over losses of $(0.22) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
TELA Bio announced FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh device for soft tissue reinforcement. Liora is the first fully resorbable synthetic product in the company's portfolio to be designed and produced in-house at its ISO 8 certified cleanroom in Malvern, PA, expanding TELA Bio's soft tissue reconstruction market footprint.
TELA Bio Says FDA Cleared Liora Resorbable Surgical Mesh For Soft Tissue Reinforcement
Craig-Hallum Initiates Coverage On TELA Bio with Buy Rating, Announces Price Target of $2
Craig-Hallum analyst Chase Knickerbocker initiates coverage on TELA Bio (NASDAQ:TELA) with a Buy rating and announces Price Target of $2.